Market Cap 624.91M
Revenue (ttm) 91.28M
Net Income (ttm) -145.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -159.10%
Debt to Equity Ratio 0.00
Volume 1,178,800
Avg Vol 718,272
Day's Range N/A - N/A
Shares Out 29.38M
Stochastic %K 37%
Beta -0.26
Analysts Strong Sell
Price Target $41.09

Latest News on ANAB

Anaptys Announces Stock Repurchase Plan

Mar 24, 2025, 9:15 AM EDT - 2 months ago

Anaptys Announces Stock Repurchase Plan


Anaptys Announces Participation in March Investor Conferences

Feb 27, 2025, 4:15 PM EST - 3 months ago

Anaptys Announces Participation in March Investor Conferences


Anaptys Announces Participation in September Investor Conferences

Aug 29, 2024, 9:15 AM EDT - 10 months ago

Anaptys Announces Participation in September Investor Conferences


AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 15, 2024, 2:14 PM EDT - 10 months ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point


Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

PGEN XOMA


Anaptys Named a BioSpace 2024 Best Places to Work Winner

Nov 7, 2023, 4:15 PM EST - 1 year ago

Anaptys Named a BioSpace 2024 Best Places to Work Winner


AnaptysBio: Upside Could Be Lying Ahead Very Nicely

Mar 30, 2023, 11:44 PM EDT - 2 years ago

AnaptysBio: Upside Could Be Lying Ahead Very Nicely